Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies

Código QR

Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies

Arthur B Epstein1, Peter T Van Hoven2, Alan Kaufman3, Warner W Carr41North Shore Contact Lens and Vision Consultants, Roslyn Heights, NY, USA; 2Primary Eyecare Group PC, Brentwood, TN, USA; 3Adult Allergy Clinic and the Division of Allergy and Immunology, Our Lady of Mercy Medical Center, Bronx, NY,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Arthur B Epstein, Peter T Van Hoven, Alan Kaufman, Warner W Carr
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/f38fcd8874054b8aa7f35084fdc2594b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Efficacy of 0.05% epinastine and 0.1% olopatadine for allergic conjunctivitis as seasonal and preseasonal treatment
por: Mizoguchi T, et al.
Publicado: (2017)

Pooled analysis of two studies evaluating efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis
por: McLaurin E, et al.
Publicado: (2017)

Treatment of allergic conjunctivitis with olopatadine hydrochloride eye drops
por: Eiichi Uchio
Publicado: (2008)

Efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis using a conjunctival allergen-challenge model
por: Torkildsen G, et al.
Publicado: (2015)

Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%
por: Jack V Greiner, et al.
Publicado: (2011)

Azelastine hydrochloride, a dual-acting anti-inflammatory ophthalmic solution, for treatment of allergic conjunctivitis
por: Patricia B Williams, et al.
Publicado: (2010)

Comparison of the latanoprost 0.005%/timolol 0.5% + brinzolamide 1% versus dorzolamide 1%/timolol 0.5% + latanoprost 0.005%: a 12-week, randomized open-label trial
por: Kanamoto T, et al.
Publicado: (2012)

Efficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5% fixed combination eyedrops from latanoprost 0.005% monotherapy
por: Inoue K, et al.
Publicado: (2012)

COMPARATIVE EVALUATION OF TACROLIMUS 0.03% OINTMENT VS OLOPATADINE 0.2% EYE DROPS IN THE TREATMENT OF VERNAL KERATOCONJUNCTIVITIS
por: Hassan Sajjad Rathore, et al.
Publicado: (2021)

The effect of topical 0.05% cyclosporine on recurrence following pterygium surgery
por: Turan-Vural E, et al.
Publicado: (2011)

Comparison of timolol 0.5% + brimonidine 0.2% + dorzolamide 2% versus timolol 0.5% + brimonidine 0.2% in a Mexican population with primary open-angle glaucoma or ocular hypertension
por: Baiza-Dur&aacute;n LM, et al.
Publicado: (2012)

Distinct domain switching in Nd0.05Ce0.95CoIn5 at low and high fields
por: D. G. Mazzone, et al.
Publicado: (2018)

Fixed combination of topical brimonidine 0.2% and timolol 0.5% for glaucoma and uncontrolled intraocular pressure
por: Anne J Lee, et al.
Publicado: (2008)

A study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to latanoprost 0.005% and timolol 0.5% dosed concomitantly in patients with open-angle glaucoma or ocular hypertension
por: Douglas J Rhee, et al.
Publicado: (2008)

Green synthesis, characterization and anti-cancer capability of Co0.5Ni0.5Nd0.02Fe1.98O4 nanocomposites
por: M.A. Almessiere, et al.
Publicado: (2022)

Administration of the fixed combination of latanoprost 0.005% and timolol 0.5% in glaucoma patients with an intraocular pressure over 30 mmHg
por: Yelda Buyru &Ouml;zkurt, et al.
Publicado: (2009)

The Bayes Factor, a Suitable Complement beyond Values of p<0.05 in Nursing Research and Education
por: Cristian Antony Ramos-Vera
Publicado: (2021)

Patient and physician perspectives on the use of cyclosporine ophthalmic emulsion 0.05% for the management of chronic dry eye
por: Deveney T, et al.
Publicado: (2018)

LiNi0.8Co0.15Al0.05O2: Enhanced Electrochemical Performance From Reduced Cationic Disordering in Li Slab
por: Peng Xiao, et al.
Publicado: (2017)

A comfort comparison of travoprost BAK-free 0.004% versus latanoprost 0.005% in patients with primary open-angle glaucoma or ocular hypertension
por: David A Godfrey, et al.
Publicado: (2009)

Impacto sobre el tamaño de las muestras en estudios nacionales si cambiara el nivel de significación estadística de α= 0,05 a α = 0,005
por: Villarroel del Pino,Luis
Publicado: (2021)

Crystal structure, thermal and electrotransport properties of NdBa1–xSrxFeCo0.5Cu0.5O5+δ (0.02 ≤ x ≤ 0.20) solid solutions
por: A. I. Klyndyuk, et al.
Publicado: (2021)

Difluprednate 0.05% versus Prednisolone Acetate Post-Phacoemulsification for Inflammation and Pain: An Efficacy and Safety Clinical Trial
por: Palacio-Pastrana C, et al.
Publicado: (2020)

Efficacy and safety of switching to latanoprost 0.005%–timolol maleate 0.5% fixed-combination eyedrops from an unfixed combination for 36 months
por: Inoue K, et al.
Publicado: (2014)

Update and clinical utility of alcaftadine ophthalmic solution 0.25% in the treatment of allergic conjunctivitis
por: Chigbu DI, et al.
Publicado: (2015)

Safety of cetirizine ophthalmic solution 0.24% for the treatment of allergic conjunctivitis in adult and pediatric subjects
por: Malhotra RP, et al.
Publicado: (2019)

Efficacy of Topical Finasteride 0.5% vs 17α-Estradiol 0.05% in the Treatment of Postmenopausal Female Pattern Hair Loss: A Retrospective, Single-Blind Study of 119 Patients
por: Alfredo Rossi, et al.
Publicado: (2020)

Comparative efficacy of bepotastine besilate 1.5% ophthalmic solution versus olopatadine hydrochloride 0.2% ophthalmic solution evaluated by patient preference
por: McCabe CF, et al.
Publicado: (2012)

Microcoulomb (0.7 ± $$\frac{0.4}{0.2}$$ 0.4 0.2 μC) laser plasma accelerator on OMEGA EP
por: J. L. Shaw, et al.
Publicado: (2021)

Efficacy and safety of 0.5% levobupivacaine versus 0.5% bupivacaine for peribulbar anesthesia
por: Pacella E, et al.
Publicado: (2013)

Assessment of ocular hypotensive effect and safety 12 months after changing from an unfixed combination to a latanoprost 0.005% + timolol maleate 0.5% fixed combination
por: Inoue K, et al.
Publicado: (2012)

Intraocular pressure reduction using a fixed combination of timolol maleate 0.5% and brimonidine tartrate 0.2% administered three times daily
por: Moisseiev E, et al.
Publicado: (2013)

Preclinical Efficacy Comparison of Cyclosporine Ophthalmic Solution 0.09% vs Cyclosporine Ophthalmic Emulsion 0.05% vs Ciclosporin Ophthalmic Emulsion 0.1% in a NOD Mouse Model of Dry Eye Disease
por: Burade V, et al.
Publicado: (2020)

Facile synthesis of g-C3N4(0.94)/CeO2(0.05)/Fe3O4(0.01) nanosheets for DFT supported visible photocatalysis of 2-Chlorophenol
por: Jamshaid Rashid, et al.
Publicado: (2019)

Localized alopecia and suppression of hypothalamic-pituitary-adrenal (HPA) axis in dogs following treatment with difluprednate 0.05% ophthalmic emulsion (Durezol®)
por: Katelin Quantz, et al.
Publicado: (2021)

A retrospective analysis of intraocular pressure changes after cataract surgery with the use of prednisolone acetate 1% versus difluprednate 0.05%
por: Kusne Y, et al.
Publicado: (2016)

Clinical utility of cyclosporine (CsA) ophthalmic emulsion 0.05% for symptomatic relief in people with chronic dry eye: a review of the literature
por: Rhee MK, et al.
Publicado: (2017)

Dose uniformity of topical corticosteroid preparations: difluprednate ophthalmic emulsion 0.05% versus branded and generic prednisolone acetate ophthalmic suspension 1%
por: William Stringer, et al.
Publicado: (2010)

Efficacy and safety of fixed-combination travoprost 0.004%/timolol 0.5% in patients transitioning from bimatoprost 0.03%/timolol 0.5% combination therapy
por: Schnober D, et al.
Publicado: (2015)

Safety and efficacy of switching from dorzolamide 1.0%/timolol maleate 0.5% eye drops to brinzolamide 1.0%/timolol maleate 0.5% eye drops
por: Inoue K, et al.
Publicado: (2015)